What's new
Fantasy Football - Footballguys Forums

This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!

Stock Thread (16 Viewers)

WFC

P/E of 8.25 and about a 6% dividend.

Even if they're a ####ty bank, that's a really good price. In for 100 after hours

 
cosjobs said:
Pretty sure a bank investment today is less risky than an airline, cruise line, or restaurant.

What does P/E go down to to be attractive with a 6% dividend?
Click to expand...
Totally agree with you which is why outside of index funds I don't own any of those and don't plan on buying them anytime soon. But if you're buying today you're guessing their earnings are going to be expectations? Also, not digging on you, just trying to understand. No dog in this fight. 

 
Last edited by a moderator:
CR69 said:
cosjobs said:
Pretty sure a bank investment today is less risky than an airline, cruise line, or restaurant.

What does P/E go down to to be attractive with a 6% dividend?
Click to expand...
Totally agree with you which is why outside of index funds I don't own any of those and don't plan on buying them anytime soon. But if you're buying today you're guessing their earnings are going to be expectations? Also, not digging on you, just trying to understand. No dog in this fight. 

Edited 21 minutes ago by CR69
Click to expand...
The large banks are heavily capitalized and actually have had those regulations loosened.  Low rates are going to be a long term drag, but it is really a question of what the losses will be.  Or if the Fed makes banks suspend their dividends/buybacks as former Fed Chair Yellen has suggested.

 
I don't know anything about the source but at the end of the article it says "Disclosure: we hold no position in CYDY either long or short and we have not been compensated for this article."  I have my doubts that the author of the article gained nothing for writing the article.

https://microcapdaily.com/why-cytodyn-inc-otcmktscydy-holds-all-the-cards/125665/

CytoDyn Inc (OTCMKTS:CYDY) has seen a spectacular rise in recent months from well under $0.50 back in December to recent highs of $3.50 per share. The stock has transformed into a volume leader regularly topping $10 million in daily trading volume and surpassing $100 million in daily dollar volume several times in recent weeks. These are heady days indead for CYDY shareholders, many of whom have been around for years supporting Nadar and co.

It is easy to get excited about CYDY as coronavirus continues its deadly march forward infecting just under 2 million people as of this writing and growing fast. There is no known cure for covid-19 but several treatments have emerged and CytoDyn’s wunderdrug Leronlimab is at the top of the pack with highly positive results coming back. The story is starting to get picked up by the national media which could spell doom for the significant short position that has built up in CYDY over the past few months.

CytoDyn Inc (OTCMKTS:CYDY) is an emerging biotech developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. The Company has been granted a “fast-track” designation for two potential uses of leronlimab – as a combination therapy with other medications for HIV patients and for patients with metastatic triple-negative breast cancer. Leronlimab blocks CCR5 (C-C motif chemokine receptor 5), a cellular receptor important in HIV infection, tumor metastases, and other diseases. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

Leronlimab which has been hailed as a possible wonder drug has demonstrated significant potential as a treatment for coronavirus (COVID-19). Leronlimab is believed to provide therapeutic benefit by enhancing the immune response while mitigating the “cytokine storm” that leads to morbidity and mortality in covid patients. The laboratory evaluation of the first four patients treated with leronlimab revealed that the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm (including IL-6 and TNF alpha) were much improved.

More than 30 patients have been administered leronlimab under EINDs authorized by the U.S. Food and Drug Administration (FDA) in over 4 hospitals and clinics throughout the country. More than 25 hospitals, to date, have requested participation in the Company’s trials. The results coming back are highly promising and are being monitored and reported on regularly in mainstream press. CEO Nader Pourhassan said, “We continue to coordinate around the clock with healthcare professionals across the country to deliver leronlimab to patients and we are in regular contact with the FDA to ensure they receive current patient data. We are planning to rapidly enroll 75 patients and report the results to the FDA as quickly as possible.”

Mitch Tracy@MitchTracy1

Potential new COVID-19 treatment leronlimab being tested on coronavirus patients. #cydy https://www.newsweek.com/potential-new-covid-19-treatment-leronlimab-first-coronavirus-patients-1497226 …

Potential new COVID-19 treatment leronlimab being tested on coronavirus patients

A Phase II clinical trial has begun investigating the drug in patients with mild-to-moderate forms of the disease.

newsweek.com

1

12:44 AM - Apr 12, 2020

Leronlimab is all over the mainstream news as it continues to show success. A recently patient who recovered in Los Angeles Samantha Mottet credits the drug “leronlimab” for her recovery from COVID-19. The patient was on a ventilator in the ICU, where doctors tried two treatments that didn’t work. That’s when her doctor and family approached Dr. Otto Yang, a professor of medicine at UCLA’s David Geffen School of Medicine, who is leading a clinical trial of a drug called “leronlimab.” Researchers are administering the drug to COVID-19 patients across the country as a new potential treatment, and Yang offered Mottet a spot in his trial.

Dr. Otto Yang said “leronlimab” is an artificial antibody that works against the second phase of the COVID-19. That’s when the body’s immune system overreacts in response to the virus. It’s administered through an injection under the skin. “That reaction causes a lot of collateral damage so a lot of the inflammation in the lungs that causes people not to be able to breathe is this collateral damage. So the idea is that it will reduce the amount of inflammation in the lungs. In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together. Then a couple of days after that, she didn’t require any oxygen at all.”

While Yang cannot be sure as to whether “leronlimab” is solely responsible for Mottet’s recovery. he said he believes there is strong evidence to support this theory.

CYDY is all over TV:

Stock Slayer@stock_slayer

$CYDY My boomer moment taking a picture of the tv yesterday, but man was I excited to see one of my OTC tickers being talked about on a national broadcast! Coverage is just getting started! #Mediabuzz #coronacure #Leronlimab #BorisJohnson #cydy #COVIDー19 #cureforcoronavirus

5

7:04 PM - Apr 8, 2020

CYDY is making big moves after the Company became one of the first biotechs to have a drug that could be effective in the global fight against coronavirus COVID-19 world epidemic. leronlimab which has been hailed as a possible wonder drug has been found to have significant potential to attack a host of diseases including cancer, HIV and now coronavirus COVID-19. A growing number of patients now with serious respiratory conditions with Covid-19 around the country are being treated with leronlimab and the results coming back are highly promising with 1 LA patient Samantha Mottet crediting “leronlimab” for her recovery from COVID-19.  The story is starting to get picked up by the national media which could spell doom for the significant short position that has built up in CYDY over the past few months. While there are dozens of big board biotechs looking for a coronavirus treatment its leronlimab from CytoDyn that keeps popping up mainstream press and on TV. We will be updating on CYDY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYDY.
Click to expand...

 
Last edited by a moderator:
Jefferson the Caregiver said:
Definitely up for getting dosed on the limeade should something terrible happen to me.

@General Malaise can I put you in charge of this one? Just let my wife know, I want the limeade!

Also have a playlist while I'm getting fed it, they can just roll this on repeat.

  • Green River
  • Green Eyed Lady
  • Green Grass and High Tides>Legalize It>Green Grass and High Tides
  • Scentless Apprentice
  • Someone Saved My Life Tonight
  • On Green Dolphin Street
  • Speak to Me/Breathe
  • Coconut
  • Sweet Leaf
  • Money
Click to expand...
I got you, brother.

 
TripItUp said:
Historically we are at very low oil prices.   Seems like a decent bet if you can go long.
Click to expand...
Already did.  MRO up 43% and Exxon up 37%.  Although have one lot of Exxon above the current price.  Wish I'd had the guts to go all in on these two.  Obviously oil wasn't going any lower than what the barrel costs.

Anyone in particular that you like?  

 
Don Hutson said:
sclosure: we hold no position in CYDY either long or short and we have not been compensated for this article."  I have my doubts that the author of the article gained nothing for writing the article.

https://microcapdaily.com/why-cytodyn-inc-otcmktscydy-holds-all-the-cards/125665/

CytoDyn Inc (OTCMKTS:CYDY) has seen a spectacular rise in recent months from well under $0.50 back in December to recent highs of $3.50 per share. The stock has transformed into a volume leader regularly topping $10 million in daily trading volume and surpassing $100 million in daily dollar volume several times in recent weeks. These are heady days indead for CYDY shareholders, many of whom have been around for years supporting Nadar and co.

It is easy to get excited about CYDY as coronavirus continues its deadly march forward infecting just under 2 million people as of this writing and growing fast. There is no known cure for covid-19 but several treatments have emerged and CytoDyn’s wunderdrug Leronlimab is at the top of the pack with highly positive results coming back. The story is starting to get picked up by the national media which could spell doom for the significant short position that has built up in CYDY over the past few months.

CytoDyn Inc (OTCMKTS:CYDY) is an emerging biotech developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. The Company has been granted a “fast-track” designation for two potential uses of leronlimab – as a combination therapy with other medications for HIV patients and for patients with metastatic triple-negative breast cancer. Leronlimab blocks CCR5 (C-C motif chemokine receptor 5), a cellular receptor important in HIV infection, tumor metastases, and other diseases. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

Leronlimab which has been hailed as a possible wonder drug has demonstrated significant potential as a treatment for coronavirus (COVID-19). Leronlimab is believed to provide therapeutic benefit by enhancing the immune response while mitigating the “cytokine storm” that leads to morbidity and mortality in covid patients. The laboratory evaluation of the first four patients treated with leronlimab revealed that the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm (including IL-6 and TNF alpha) were much improved.

More than 30 patients have been administered leronlimab under EINDs authorized by the U.S. Food and Drug Administration (FDA) in over 4 hospitals and clinics throughout the country. More than 25 hospitals, to date, have requested participation in the Company’s trials. The results coming back are highly promising and are being monitored and reported on regularly in mainstream press. CEO Nader Pourhassan said, “We continue to coordinate around the clock with healthcare professionals across the country to deliver leronlimab to patients and we are in regular contact with the FDA to ensure they receive current patient data. We are planning to rapidly enroll 75 patients and report the results to the FDA as quickly as possible.”

Mitch Tracy@MitchTracy1

Potential new COVID-19 treatment leronlimab being tested on coronavirus patients. #cydy https://www.newsweek.com/potential-new-covid-19-treatment-leronlimab-first-coronavirus-patients-1497226 …

Potential new COVID-19 treatment leronlimab being tested on coronavirus patients

A Phase II clinical trial has begun investigating the drug in patients with mild-to-moderate forms of the disease.

newsweek.com

1

12:44 AM - Apr 12, 2020

Leronlimab is all over the mainstream news as it continues to show success. A recently patient who recovered in Los Angeles Samantha Mottet credits the drug “leronlimab” for her recovery from COVID-19. The patient was on a ventilator in the ICU, where doctors tried two treatments that didn’t work. That’s when her doctor and family approached Dr. Otto Yang, a professor of medicine at UCLA’s David Geffen School of Medicine, who is leading a clinical trial of a drug called “leronlimab.” Researchers are administering the drug to COVID-19 patients across the country as a new potential treatment, and Yang offered Mottet a spot in his trial.

Dr. Otto Yang said “leronlimab” is an artificial antibody that works against the second phase of the COVID-19. That’s when the body’s immune system overreacts in response to the virus. It’s administered through an injection under the skin. “That reaction causes a lot of collateral damage so a lot of the inflammation in the lungs that causes people not to be able to breathe is this collateral damage. So the idea is that it will reduce the amount of inflammation in the lungs. In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together. Then a couple of days after that, she didn’t require any oxygen at all.”

While Yang cannot be sure as to whether “leronlimab” is solely responsible for Mottet’s recovery. he said he believes there is strong evidence to support this theory.

CYDY is all over TV:

Stock Slayer@stock_slayer

$CYDY My boomer moment taking a picture of the tv yesterday, but man was I excited to see one of my OTC tickers being talked about on a national broadcast! Coverage is just getting started! #Mediabuzz #coronacure #Leronlimab #BorisJohnson #cydy #COVIDー19 #cureforcoronavirus

5

7:04 PM - Apr 8, 2020

CYDY is making big moves after the Company became one of the first biotechs to have a drug that could be effective in the global fight against coronavirus COVID-19 world epidemic. leronlimab which has been hailed as a possible wonder drug has been found to have significant potential to attack a host of diseases including cancer, HIV and now coronavirus COVID-19. A growing number of patients now with serious respiratory conditions with Covid-19 around the country are being treated with leronlimab and the results coming back are highly promising with 1 LA patient Samantha Mottet crediting “leronlimab” for her recovery from COVID-19.  The story is starting to get picked up by the national media which could spell doom for the significant short position that has built up in CYDY over the past few months. While there are dozens of big board biotechs looking for a coronavirus treatment its leronlimab from CytoDyn that keeps popping up mainstream press and on TV. We will be updating on CYDY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYDY.
Click to expand...
Click to expand...
So with all the good news out recently, why are we stuck in idle?

 
BassNBrew said:
Already did.  MRO up 43% and Exxon up 37%.  Although have one lot of Exxon above the current price.  Wish I'd had the guts to go all in on these two.  Obviously oil wasn't going any lower than what the barrel costs.

Anyone in particular that you like?  
Click to expand...
I'm thinking of straight Oil commodity...WTI.

 
BassNBrew said:
Already did.  MRO up 43% and Exxon up 37%.  Although have one lot of Exxon above the current price.  Wish I'd had the guts to go all in on these two.  Obviously oil wasn't going any lower than what the barrel costs.

Anyone in particular that you like?  
Click to expand...
We just had a 13.4 MMbbl/d cut and oil barely moved. Demand destruction is anywhere from 20-30MMbbl/d so until that equation normalizes, oil could very well fall into the teens. There was talk US producers could pay companies to take their oil instead of having to shut in their wells. 

I think the real play in oil is tankers. They're turning into floating storage for oil and will be filled to the gills for the foreseeable future. 

 
Earnings season will be a complete cluster except for the obvious 3M’s of the world. But the market has to know that. Many will not even provide guidance going forward. Throwing darts. 

 
cosjobs said:
Pretty sure a bank investment today is less risky than an airline, cruise line, or restaurant.

What does P/E go down to to be attractive with a 6% dividend?
Click to expand...
I'll keep my JETS. but yes, individual airlines are risky. I'll bet on the industry. 

 
sporthenry said:
We just had a 13.4 MMbbl/d cut and oil barely moved. Demand destruction is anywhere from 20-30MMbbl/d so until that equation normalizes, oil could very well fall into the teens. There was talk US producers could pay companies to take their oil instead of having to shut in their wells. 

I think the real play in oil is tankers. They're turning into floating storage for oil and will be filled to the gills for the foreseeable future. 
Click to expand...
Any suggestions here that aren't Greek.

 
Don Hutson said:
I don't know anything about the source but at the end of the article it says "Disclosure: we hold no position in CYDY either long or short and we have not been compensated for this article."  I have my doubts that the author of the article gained nothing for writing the article.
Click to expand...
https://microcapdaily.com/sec-disclosure/

The motivation is explained at the link. I like this part the best:

“DO NOT BELEIVE anything you read in the articles, many of them are way out of date or just plain wrong. Always do your own due diligence and don’t make any investment decisions based on these articles. View MicroCapDaily as a great place to find unknown penny stocks, a starting place but then go out and do your own research because the information in these articles is in no way reliable and is wrong most of the time.”

 
Don't Noonan said:
I know things have stabilized a little bit lately in the bond market thanks to the Fed but spreads are still pretty wide compared to normal.  Anyone putting some cash to work in high yield, floating rate, or investment grade bonds?  

I added EIFHX Eaton Vance Floating Rate on March 24th and it is up over 10% since then.  Considering adding to high yield or perhaps even muni high yield.
Click to expand...
I added a big chunk of BHK on 3/24/20 (coincidentally) .  So far, up 12.7%

 
I may have to open a position in CAT this morning. 

Changing my Roth IRA to half Paul Merriman's portfolio, half stuff I like.  No more TZA. While I'm better off having bought that and staying long in the market (so far) it's not a thing I meant to keep long term, had planned to get rid of it last week but kept it thinking the market surely would crash again. 🤷‍♂️

 
Mancini - In this 3 week $SPX rally we've only had 1 pullback lasting more than one day from March 31-April 1. For the next one- ideal would be 1 more pop higher.Some big levels above as shown in my chart including the first 50dma test at 2880 and the 61.8% fib of the whole selloff ~2930

Someone replied: I've given up I'm closing all my shorts at open. Can't hold them anymore it's too stressful and the market is beyond irrational. Think I'm just gonna trade Forex from now on $SPY.

This is how it works. Can't remember who posted it over the weekend but: Short covering, followed by momentum players, followed by FOMOs.

So I'm probably going with this> One more high and then I'm back out.

 
I get that these don't work together perfectly, always but it's weird to see the Russell 2000 down 3% and the other 3 indexes up over 2%

 
lod001 said:
Mancini - In this 3 week $SPX rally we've only had 1 pullback lasting more than one day from March 31-April 1. For the next one- ideal would be 1 more pop higher.Some big levels above as shown in my chart including the first 50dma test at 2880 and the 61.8% fib of the whole selloff ~2930

Someone replied: I've given up I'm closing all my shorts at open. Can't hold them anymore it's too stressful and the market is beyond irrational. Think I'm just gonna trade Forex from now on $SPY.

This is how it works. Can't remember who posted it over the weekend but: Short covering, followed by momentum players, followed by FOMOs.

So I'm probably going with this> One more high and then I'm back out.
Click to expand...
I'm very tempted to thin a bunch of my stocks. I sold barely anything during the crash and I'm basically even in my two cash accounts (thanks mainly to AMZN being up). I'm down about 10% and change in my IRA where I have 0 AMZN and the high I hit was a high high due to all the growth stocks like TTD, MDB, OKTA, etc. That's even with a 100 shares of LK blowing up and TWLO getting hit after missing earnings (hit revenue) the last quarter.

I don't trust this rally at all. The economy is really bad. My sister's a doctor and mentioned many doctors and hospitals bleeding cash. Tons of people not working and even large companies are tightening their belts.

I need to really look at my capital gains in the cash accounts and which stocks (stuff like AMZN, ROKU, maybe CYDY, that will come through a downdraft ok). Getting whacked with a 40% tax bill instead of 15% gives you some room for a drop.

 
You must log in or register to reply here.

Similar threads

Andrew74
2025 FBG Stock Contest
2
Replies
77
Views
4K
Andrew74
Andrew74
Andrew74
2024 FBG Stock Contest
2 3
Replies
127
Views
7K
McBokonon
McBokonon
Joey Wright
2025-2026 NCAA College Basketball Thread
Replies
6
Views
198
SpurrierisisGod
SpurrierisisGod

Users who are viewing this thread

Total: 14 (members: 0, guests: 14)
Back
Top